$258.28
Value $28.4B
DGX and LLY stock compared: price, dividend, valuation and results, from SEC filings.
$258.28
Value $28.4B
$1,386.37
Value $1.31T
Quest Diagnostics (DGX) has a market value of $28.4B and Eli Lilly and Company (LLY) $1.31T. Over the last year, with dividends, DGX moved +41.0% and LLY +36.5%. The P/E is 25.1 for DGX and 47.4 for LLY. Dividend yield: DGX 1.31%, LLY 0.46%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
DGX$28.4B
LLY$1.31T
LLY is 46 times DGX
Revenue, 12 months
DGX$11.8B
LLY$86.5B
LLY is 7.3 times DGX
Net income, 12 months
DGX$1.1B
LLY$27.6B
LLY is 24 times DGX
Operating margin
DGX14.5%
LLY–
ROIC
DGX10.2%
LLY35.5%
25.3 points apart
P/E
DGX25.1
LLY47.4
LLY is 1.9 times DGX
Dividend yield
DGX1.3%
LLY0.5%
0.8 points apart
5-year return
DGX+92.4%
LLY+454.2%
361.8 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
DGX+92.4%
LLY+454.2%
| Period | DGXWith dividends | LLYWith dividends |
|---|---|---|
| 1 year since November 17, 2025 | +41.0%Price +38.7% | +36.5%Price +35.7% |
| 3 years since November 17, 2023 | +102.7%+26.5% a yearPrice +91.5% | +139.0%+33.7% a yearPrice +134.3% |
| 5 years since November 17, 2021 | +92.4%+14.0% a yearPrice +74.7% | +454.2%+40.8% a yearPrice +430.8% |
| 10 years since November 18, 2016 | +267.4%+13.9% a yearPrice +201.9% | +2,003.4%+35.6% a yearPrice +1,708.2% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
DGXQuest DiagnosticsLLYEli Lilly and Company
| Price | $258.28 | $1,386.37 |
|---|---|---|
| Market value | $28.4B | $1.31T |
| Enterprise value (EV) | $33.1B | $1.35T |
| P/E | 25.1 | 47.4 |
| P/E, 5-year median | 19.6 | 49.9 |
| P/B | 3.7 | 32.5 |
| EV/EBIT | 19.2 | 38.9 |
| Free cash flow yield | 4.9% | 1.5% |
| Revenue, 12 months | $11.8B | $86.5B |
|---|---|---|
| Net income, 12 months | $1.1B | $27.6B |
| Free cash flow, 12 months | $1.4B | $19.7B |
| Earnings per share, 12 months | $10.04 | $30.81 |
| Revenue growth, year on year | 11.8% | 44.7% |
| Revenue growth a year, past | +3.2%over 5 years | +21.6%over 5 years |
| EPS growth a year, past | -3.5%over 5 years | +27.6%over 5 years |
| Gross margin | 33.1% | 83.6% |
|---|---|---|
| Operating margin | 14.5% | – |
| Net margin | 9.5% | 31.9% |
| ROIC | 10.2% | 35.5% |
| ROE | 15.3% | 88.6% |
| Cash | $797M | $4.9B |
|---|---|---|
| Total debt | $6.3B | $49.5B |
| Net debt / EBITDA | 2.1 | 1.2 |
| Interest cover | – | 38.9× |
| Dividend yield | 1.3% | 0.5% |
|---|---|---|
| Dividend per share, 12 months | $3.38 | $6.34 |
| Dividend growth a year, past | +7.5%over 5 years | +15.2%over 5 years |
| Buyback yield | 1.6% | 0.3% |
| Shareholder yield | 2.9% | 0.8% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Eli Lilly and Company ($1.31T) is about 46.1 times Quest Diagnostics ($28.4B), at today's prices.
Since November 18, 2016, DGX's price moved +201.9% and LLY's +1,708.2%. With dividends: DGX +267.4% (+13.9% a year), LLY +2,003.4% (+35.6% a year). Past returns do not predict future ones.
The dividend yield at today's price is 1.31% for Quest Diagnostics and 0.46% for Eli Lilly and Company. Over the last twelve months they paid $3.38 and $6.34 per share.
At today's price, the P/E is 25.1 for DGX and 47.4 for LLY. The median of the last five years was 19.6 and 49.9, which shows where each stands against its own past.
Over the last twelve months, the net margin was 9.5% for Quest Diagnostics and 31.9% for Eli Lilly and Company, and the operating margin 14.5% and –. Revenue was $11.8B and $86.5B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.